Journal
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
Volume 359, Issue 5, Pages 287-295Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjms.2020.02.007
Keywords
WASF3; Gastric cancer; Oxaliplatin; Autophagy; Atg12
Categories
Funding
- National Natural Science Foundation of China [81572287, 81772499]
- Natural Science Foundation of Hubei Province [2017CFB555]
- Health commission of Hubei Province scientific research project [WJ2017M142, WJ2019H132]
Ask authors/readers for more resources
Background: Gastric cancer is one of the most aggressive tumors, usually resulting in metastasis, and therapies for advanced gastric cancer remain limited. Drug resistance is the main reason for chemotherapeutic failure in gastric cancer. Wiskott-Aldrich syndrome protein family member 3 (WASF3) is required for invasion and metastasis of different cancers. However, there has been little study of WASF3 expression involvement in gastric cancer. In this study, we explored the role of WASF3 in the sensitivity of gastric cancer to oxaliplatin, and the underlying mechanisms. Methods: We silenced WASF3 using WASF3-siRNA in MGC803 cells. Then, CCK-8, flow cytometry and transwell assay were performed to study the effect of WASF3 silencing on proliferation, migration, invasiveness and apoptosis of MGC803 cells. Moreover, we evaluated the potential mechanism in vitro to determine the sensitization to oxaliplatin induced by WASF3. Results: WASF3 silencing by small interfering RNA inhibited the proliferation, migration and invasiveness of gastric cancer cells. We also observed that WASF3 knockdown promoted cell apoptosis and enhanced oxaliplatin sensitivity. Furthermore, the sensitization to oxaliplatin induced by WASF3 knockdown depended on the inhibition of Atg12-mediated autophagy. Conclusions: Our analysis demonstrates WASF3 targeting is a new potential therapeutic strategy for gastric cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available